CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-12 | Kerr Douglas Chief Medical Officer | Grant or award | +85,000 | 172,510 | ||
| 2026-02-12 | Kerr Douglas Chief Medical Officer | Grant or award · Stock option (right to buy) | +130,000 | 130,000 | ||
| 2026-02-12 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award | +60,000 | 154,729 | ||
| 2026-02-12 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award · Stock option (right to buy) | +90,000 | 90,000 | ||
| 2026-02-12 | Lucera Erick Chief Financial Officer | Grant or award | +65,000 | 131,100 | ||
| 2026-02-12 | Lucera Erick Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2025-12-22 | Karnani Vikram Director | Grant or award · Stock option (right to buy) | +59,665 | 59,665 | ||
| 2025-12-05 | Cox John CEO & President | Sale 10b5-1 | −2,662 | $20.72 | $55K | 196,877 |
| 2025-12-05 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −880 | $20.72 | $18K | 87,510 |
| 2025-12-05 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −144 | $20.72 | $3K | 94,729 |
| 2025-10-01 | Posner Brian S Director | Grant or award · Stock option (right to buy) | +70,000 | 70,000 | ||
| 2025-09-05 | Cox John CEO & President | Sale 10b5-1 | −2,640 | $13.41 | $35K | 199,539 |
| 2025-09-05 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −144 | $13.41 | $2K | 94,873 |
| 2025-09-05 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −873 | $13.41 | $12K | 88,390 |
| 2025-09-04 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −894 | $13.27 | $12K | 95,017 |
| 2025-09-04 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −3,552 | $13.27 | $47K | 89,263 |
| 2025-07-16 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award · Stock option (right to buy) | +51,255 | 51,255 | ||
| 2025-07-16 | Kerr Douglas Chief Medical Officer | Grant or award · Stock option (right to buy) | +65,110 | 65,110 | ||
| 2025-07-16 | Cox John CEO & President | Grant or award · Stock option (right to buy) | +197,285 | 197,285 | ||
| 2025-07-15 | Cox John CEO & President | Gift | −10,000 | 232,179 |
Page 8 of 29 · 561 trades